The phase 2 trial will assess effectiveness of monoclonal antibodies in conjunction with remdesivir
Sitagliptin May Cut Mortality in T2DM Patients With COVID-19
Sitagliptin at time of hospitalization linked to reduced mortality, improved clinical outcomes
Black Race Tied to COVID-19 Admissions, but Not Deaths
In-hospital mortality higher for Asian patients, despite lower risk for hospital admission
COVID-19 Antibody Treatment Study Paused
ACTIV-3 study, testing use of an antibody therapy with remdesivir, paused ‘out of an abundance of caution’
Immune Responses Long-Lasting After Serious COVID-19
IgG levels remain elevated for four months in patients with symptoms lasting for 14 days
Individuals With Blood Group O Have Lower Risk for COVID-19
And more COVID-19 patients with blood group A or AB require mechanical ventilation, CRRT